Biogen Stock Surges on Reports of Samsung Deal, Then Tanks after Reports are Denied — What Should Investors Do?

Business Man Using Mobile phone Investment discussing and analysis graph stock market trading,stock chart concept.
SARINYAPINNGAM / Getty Images/iStockphoto

Shares of Biogen fell hard in pre-market trading Thursday, a day after they surged on reports that the biotech was being acquired by Samsung — something Samsung later denied.

See: Samsung Delivers Strong Q2 Profit Gains As Chip Shortage Hits OLED Smartphones and TVs
Find: Every Stock That Warren Buffett Owns, Ranked

On Wednesday The Korea Economic Daily, citing unnamed investment banking sources, reported that Samsung is in negotiations to buy Biogen for about $42 billion — a 20% premium on Biogen’s current market value of $35 billion. The news was later reported by U.S. financial websites, helping to push Biogen’s stock price up more than 9% to $258.31 on Wednesday.

That rally didn’t continue into Thursday morning, however, as Samsung officials have been busy denying that it has plans to acquire Biogen. A Samsung spokesperson told Barron’s in an emailed statement that the report was groundless, Barron’s reported. Meanwhile, Biogen told Barron’s it does not comment on market rumors and/or speculation.

Samsung BioLogics, the biotech unit of Samsung Group, also denied the buyout rumors, saying in a regulatory filing that the report was “not true” without providing any more details, Reuters reported.

Building Wealth

See: 29 Stocks That Every Retiree Should Own
Find: 7 Companies Likely To Go Public in 2022

What is true is that Biogen’s stock price fell as much as 15% in pre-market trading Thursday as the air was taken out of the buyout balloon.

There’s nothing new about companies denying buyout rumors before they have a chance to announce the buyout themselves, and there is certainly reason to believe Samsung might have an interest in Biogen. So if you’re looking to cash in Biogen’s potential as an acquisition target, maybe don’t give up just yet.

As Reuters noted, Samsung Group earlier this year said it will invest 240 trillion won ($206 billion) over the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics.

And as Barron’s reported, Samsung already has a relationship with Biogen, which holds a stake in Samsung Bioepis, a unit that develops biosimilar drugs.

More From GOBankingRates

Share this article:

facebook sharing button
twitter sharing button
linkedin sharing button
email sharing button
Building Wealth

About the Author

Vance Cariaga is a London-based writer, editor and journalist who previously held staff positions at Investor’s Business Daily, The Charlotte Business Journal and The Charlotte Observer. His work also appeared in Charlotte Magazine, Street & Smith’s Sports Business Journal and Business North Carolina magazine. He holds a B.A. in English from Appalachian State University and studied journalism at the University of South Carolina. His reporting earned awards from the North Carolina Press Association, the Green Eyeshade Awards and AlterNet. In addition to journalism, he has worked in banking, accounting and restaurant management. A native of North Carolina who also writes fiction, Vance’s short story, “Saint Christopher,” placed second in the 2019 Writer’s Digest Short Short Story Competition. Two of his short stories appear in With One Eye on the Cows, an anthology published by Ad Hoc Fiction in 2019. His debut novel, Voodoo Hideaway, was published in 2021 by Atmosphere Press.
Learn More


See Today's Best
Banking Offers